LONDON: GlobalData Plc, a prominent data, analytics, and insights platform, has announced significant progress in its M&A strategy with the completion of its acquisition of Deallus, a market-leading competitive intelligence solutions provider specializing in the global life sciences sector.

With a robust 20-year history, Deallus has amassed deep sector expertise, supporting clients across critical therapy areas such as Oncology, Neuroscience, Vaccines, Rare Diseases, Cell & Gene, and Immunology. This acquisition is set to strengthen GlobalData’s relationships with major pharmaceutical brands, enhancing the potential to deliver greater value to its clients.

The acquisition was funded by the Group’s newly announced debt facilities and officially completed on December 31, 2024. Notably, this marks the fourth acquisition finalized in the second half of 2024, following the acquisitions of Business Trade Media International, LinkUp, and Celent, which were also completed on the same day.

An update on the Group’s trading and full-year 2024 results is expected on January 14, 2025, where further details on the positive impact of recent M&A activities will be provided.

Mike Danson, CEO of GlobalData Plc, remarked, “This acquisition further enhances our capabilities in delivering life sciences solutions, allowing us to offer even more comprehensive insights and services to our clients. Deallus’s deep sector expertise and client-first mindset align perfectly with our mission to empower decision-makers navigating the complexities of the healthcare landscape. Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders.”

GlobalData Plc to acquire Celent, a leading research and advisory firm